Dimensional Fund Advisors LP Buys 62,143 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Dimensional Fund Advisors LP lifted its stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 86.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 134,353 shares of the company's stock after purchasing an additional 62,143 shares during the quarter. Dimensional Fund Advisors LP owned 0.17% of Trevi Therapeutics worth $553,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of TRVI. Jump Financial LLC bought a new stake in shares of Trevi Therapeutics in the 4th quarter worth $89,000. Walleye Capital LLC purchased a new stake in shares of Trevi Therapeutics during the fourth quarter valued at $136,000. XTX Topco Ltd bought a new stake in Trevi Therapeutics in the 4th quarter worth about $277,000. Barclays PLC raised its position in Trevi Therapeutics by 64.1% in the 4th quarter. Barclays PLC now owns 156,267 shares of the company's stock worth $643,000 after buying an additional 61,035 shares during the last quarter. Finally, Summit Investment Advisors Inc. raised its position in Trevi Therapeutics by 84.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock worth $26,000 after buying an additional 2,894 shares during the last quarter. Institutional investors own 95.76% of the company's stock.

Trevi Therapeutics Price Performance

Shares of TRVI stock traded down $0.02 during trading hours on Tuesday, reaching $6.47. 999,579 shares of the company traded hands, compared to its average volume of 1,187,177. Trevi Therapeutics, Inc. has a 12-month low of $2.30 and a 12-month high of $7.39. The company has a market cap of $646.31 million, a P/E ratio of -14.70 and a beta of 0.62. The firm has a 50-day moving average price of $6.29 and a 200 day moving average price of $4.68.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.04. Sell-side analysts predict that Trevi Therapeutics, Inc. will post -0.49 EPS for the current year.

Insider Transactions at Trevi Therapeutics

In other news, insider Farrell Simon sold 81,313 shares of the company's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $6.75, for a total value of $548,862.75. Following the completion of the transaction, the insider now owns 76,900 shares of the company's stock, valued at $519,075. This represents a 51.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Jennifer L. Good sold 5,263 shares of Trevi Therapeutics stock in a transaction that occurred on Friday, March 21st. The shares were sold at an average price of $6.58, for a total value of $34,630.54. Following the sale, the chief executive officer now directly owns 213,313 shares in the company, valued at $1,403,599.54. This trade represents a 2.41% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 18.30% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on TRVI shares. Oppenheimer raised their price target on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. HC Wainwright restated a "buy" rating and issued a $12.50 target price on shares of Trevi Therapeutics in a report on Wednesday, March 19th. Needham & Company LLC reiterated a "buy" rating and set a $24.00 target price on shares of Trevi Therapeutics in a research note on Tuesday. Raymond James raised Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and increased their price target for the company from $9.00 to $29.00 in a report on Monday, March 10th. Finally, D. Boral Capital restated a "buy" rating and issued a $21.00 price target on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Seven equities research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $17.56.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.